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Objectives. The ST segment monitoring substudy of the Global 
Utilization of Streptokinase and Tissue Plasminogen Activator for 
Occluded Coronary Arteries (GUSTO-I) trial compared the speed 
and stability of ST segment recovery among four thrombolytic 
strategies for acute myocardial infarction. 
Background. Rapid resolution of ST segment elevation has been 
suggested as a noninvasive marker of infarct-related artery pa- 
tency. We expected that patients treated with accelerated recom- 
binant tissue-type plasminogen activator (rt-PA) would show a 
quicker recovery than that of other patients but that those treated 
with streptokinase would show greater stability of recovery. 
Methods. ST segment monitoring was initiated in 1,067 patients 
within 30 min of the start of thrombolysis and continued for > 18 h 
with the use of a three-channel continuous vectorcardiographic 
monitor, a 12-lead continuous electrocardiographic (ECG) mon- 
itor or a three-channel (V2, Vs, aVF) Holter ambulatory ECG 
monitor. 
Results. Time to 50% recovery could be assessed in 618 patients 
and was similar in the four treatment groups: median 45 min with 
streptokinase/subcutaneous heparin, 45 min with streptokinase/ 
intravenous heparin, 42 min with accelerated rt-PA and 47 rain 
with combination therapy (p = 0.7). No significant difference 
among the thrombolytic regimens was shown with the three 
monitors used. Time to initiation of ST segment analysis was 
directly related to time to 50% recovery (p = 0.0001) and was its 
best predictor in a multiple regression model. ST segment eleva- 
tion recurred equally in each treatment group (-36%, p = 0.9) 
but was significantly more common in patients with a patent 
infarct-related artery (p = 0.033) or a low ejection fraction (p = 
0.001). 
Conclusions. The greater 90-min patency seen with accelerated 
rt-PA in the angiographic substudy did not correlate with a 
shorter time to 50% ST segment recovery, possibly because of 
technical limitations and study design. The similar rates of 
recurrent ischemia (as assessed by ST elevation) among the 
regimens support the similar infarction and reocclusion rates 
seen in the main trial and angiographie substudy. 
(JAm Coil Cardiol 1995;25:1552-7) 
Rapid resolution of ST segment elevation has been related to 
early arterial patency in patients with acute myocardial infarc- 
tion (1-6) and can be used as a simple and readily available 
marker for assessment of thrombolytic efficacy (7). The 
recently reported Global Utilization of Streptokinase and 
Tissue Plasminogen Activator for Occluded Coronary Arteries 
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(GUSTO-I) trial (8) and its angiographic substudy (9) have 
demonstrated improved clinical outcomes and angiographic 
arterial patency in patients treated with an accelerated regi- 
men of tissue-type plasminogen activator (rt-PA) as compared 
with findings in patients treated with streptokinase. The goal of 
the GUSTO ST segment monitoring substudy was to provide a 
noninvasive assessment of the speed and stability of reperfu- 
sion. The primary hypotheses were 1) that resolution of ST 
segment elevation as measured by time to 50% ST segment 
recovery would be faster in patients treated with regimens of 
accelerated rt-PA than in patients treated with streptokinase, 
and 2) that recurrent ST elevation, reflecting early reocclusion, 
would occur less frequently in patients treated with streptoki- 
nase than in those treated with rt-PA. 
Methods  
The protocol and the results of the GUSTO trial have been 
published previously (8). Eligible patients presented to a 
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participating hospital <6 h after the onset of symptoms with 
chest pain lasting ->20 rain, accompanied by electrocardio- 
graphic (ECG) signs of --0.1-mV ST segment elevation i  two 
or more limb leads or ->0.2-mV elevation in two or more 
contiguous precordial eads. Exclusion criteria were those 
conventionally used for administration f thrombolytic therapy 
(8). Eligible patients were randomized to receive one of four 
regimens: 1) streptokinase, 1.5 million U over 60 min, with 
subcutaneous heparin in a dose of 12,500 U twice daily, 
beginning 4 h after the start of thrombolytic therapy; 
2) streptokinase, 1.5 million U over 60 min, with an intrave- 
nous heparin bolus of 5,000 U then 1,000 U/h; 3) accelerated 
rt-PA bolus of 15 mg, 0.75 mg/kg body weight over 30 min and 
0.5 mg/kg over the next 60 min with the same intravenous 
heparin regimen; or 4) the combination of intravenous rt-PA 
(1.0 mg/kg over 60 min, not to exceed 90 mg, with 10% given 
as a bolus) and streptokinase (1.0 million U over 60 min) given 
simultaneously with the same intravenous heparin. All patients 
received chewable aspirin, ->160 rag, followed by a dose of 160 
to 325 mg/day. Patients without a contraindication to beta- 
adrenergic blockade received intravenous atenolol, 5mg, given 
in two divided doses, followed by oral therapy of 50 to 200 mg 
daily. All other medications were prescribed at the discretion 
of the attending physician. 
The majority of patients who underwent continuous ST 
segment monitoring as part of this substudy were also partic- 
ipants in the angiographic substudy (9) in which patients were 
randomly assigned to coronary angiography after thrombolytic 
therapy at 90 min, 180 min, 24 h or 5 to 7 days. Half of the 
patients were assigned to the 90-min and 5- to 7-day follow-up 
angiographic study to allow analysis of reocclusion and ven- 
tricular function (9). 
ST segment monitoring was begun preferably within 30 min 
of the start of thrombolytic treatment and continued for ->18 h. 
To allow a universal evaluation ofST segment response, one of 
three ST segment monitoring devices was used: a three- 
channel (Frank orthogonal X, Y, Z leads) continuous vector- 
cardiographic monitor (MIDA 1000, Ortivus Medical, Stock- 
holm, Sweden), a 12-lead continuous ECG monitor (ST-100, 
Mortara Instrument) or a three-channel (bipolar modified V2, 
V s, aVF) Holter ambulatory ECG monitor (Marquette 8000 
Holter Scanner, Marquette Electronics). ST segment analysis 
was first performed with all personnel unaware of treatment 
assignment and angiographic outcome in three core laborato- 
ries. Electrocardiographic editing and interpretation were per- 
formed by an experienced operator using a computer-assisted 
device. The technical details of the ST segment analysis for the 
three monitoring devices have been summarized elsewhere 
(10). 
Comparison across the four treatment groups was carried 
out with respect to two end points: 1) resolution of ST segment 
elevation, defined as time to 50% ST recovery observed in the 
lead with the greatest baseline ST segment shift identified from 
either the monitoring device or the admission 12-lead ECG; 
2) episodes of recurrent ST segment elevation in the same 
lead, defined as ->0.1-mV shift from baseline after 50% 
resolution had occurred, lasting ->1 min and separated from 
other episodes by ->1 min. 
Patients were excluded from analysis of time to 50% 
recovery because of time delay of ->1 h in initiating recording 
from the time of onset of thrombolytic therapy; inadequate 
(<0.2-mV) peak ST segment elevation to allow detection of ST 
segment elevation recovery; or a significant data gap (absence 
of data or inability to interpret ST segments) for ->1 h during 
the 1st 3 h of recording. Excluded from analysis of recurrent 
ST elevation were patients with <18 h of effective monitoring 
time or a data gap of >50% of monitoring time and patients 
without 50% recovery. To exclude ST segment shift in re- 
sponse to contrast injection or mechanical revascularization, 
ST segment analysis was not performed uring the time of the 
coronary angiogram. 
Statistical analysis. The primary end points of time to 50% 
recovery and recurrent ST segment elevation were not distrib- 
uted normally and are therefore described using median, 25th 
and 75th percentiles. Comparisons for the primary end points 
between the predefined rt-PA-containing and streptokinase 
combined groups were performed with a Wilcoxon test and all 
four treatment groups were compared by using the Kruskal- 
Wallis test. The distribution of the primary end points was 
normalized by means of log transformation, and a multiple 
regression model was employed to define the best predictors of 
time to 50% recovery of ST segment elevation and recurrent 
episodes of ST elevation. Because three monitoring devices 
were used for ST segment analysis, time to 50% recovery of ST 
segment elevation was compared among the four thrombolytic 
regimens by a two-way analysis of variance. 
Baseline clinical characteristics of patients in the four 
treatment groups were compared by analysis of variance (for 
continuous variables distributed normally) and chi-square 
analysis (for discrete variables). 
Resu l ts  
Of 1,067 patients who underwent ST segment monitoring 
with one of the three devices, the data of 97 were technically 
unanalyzable. With respect to assessment of time to recovery, 
176 patients were excluded because of time to monitor hookup 
->1 hour after initiation of thrombolytic therapy, 94 because of 
peak ST elevation <0.2 mV, 60 because of a data gap and 22 
because of data entry problems that precluded adequate 
assessment of the relation between initiation of thrombolytic 
therapy and onset of monitoring. In the remaining 618 patients 
assessment of 50% ST recovery was possible. 
Comparison of the baseline features and in-hospital mor- 
tality for these 618 patients among the four treatment groups 
(Table 1) revealed no significant differences and showed 
similarity to the overall population of the GUSTO trial (8). 
Comparison of the baseline characteristics and in-hospital 
mortality of patients who were and were not included in this 
study did not show significant differences. With respect o 
detection of recurrent ST segment elevation, 171 patients were 
excluded because of a monitoring time <18 h, 65 because of a 
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Table 1. Baseline Clinical Characteristics of the Four Treatment Groups 
SK + SC Heparin SK + IV Heparin Accel rt-PA rt-PA + SK p 
(n = 169) (n = 144) (n = 152) (n = 153) Value 
Age (yr) 60 (52,69) 62 (51,70) 61 (50,70) 59 (53,70) 1.0 
Gender (M/F) 112/40 109/35 118/35 132/37 0.8 
History of hypertension (%) 56 (33%) 55 (38%) 57 (38%) 66 (43%) 0.3 
Diabetes mellitus (%) 21 (12%) 15 (10%) 19 (12%) 27 (18%) 0.3 
History of smoking (%) 126 (75%) 95 (67%) 96 (64%) 102 (72%) 0.15 
Previous MI 23 (26%) 19 (21%) 22 (25%) 25 (28%) 0.9 
Admission heart rate (beats/min) 72 (62,84) 75 (65,85) 70 (60,84) 73 (61,86) 0.3 
Admission systolic BP (mm Hg) 126 (110,140) 130 (114,142) 130 (115,145) 130 (115,143) 0.5 
Admission diastolic BP (ram Hg) 78 (70,85) 80 (70,90) 80 (70,90) 80 (70,90) 0.5 
Killip class 
I 151 128 138 129 
II 15 14 11 20 
III 2 1 2 3 0.9 
IV 1 1 1 1 
MI location 
Anterior 73 53 62 61 
Inferior 90 84 87 90 0.5 
Other 6 7 3 2 
Ejection fraction (%) 60 (51,70) 59 (49,71) 60 (47,70) 60 (48,67) 0.6 
In-hospital deaths 7 (4%) 10 (7%) 6 (4%) 9 (6%) 0.6 
Continuous variables hown are median values, with 25th and 75th percentiles in parentheses. Accel rt-PA = accelerated recombinant tissue-type plasminogen 
activator; BP = blood pressure; F = female; IV = intravenous; M = male; MI = myocardial infarction; SC = subcutaneous; SK = streptoldnase. 
>50%-data gap during monitoring and 49 because of an 
absence of resolution of ST segment elevation ->50%. Thus 
there were 694 patients for whom assessment of recurrent ST 
elevation was possible. Again, these patients had characteris- 
tics similar to those of the other GUSTO patient groups. 
Speed of reperfusion. Time to 50% recovery of ST segment 
elevation (as a marker of reperfusion) was similar in patients 
receiving rt-PA-containing regimens (accelerated rt-PA and 
combination group) and those who received streptokinase only 
(median 45 [25th and 75th percentiles 22,68] rain vs. 45 [23,75] 
rain, p = 0.4). The distribution of time from initiation of 
thrombolytic therapy to 50% recovery of ST segment elevation 
(Fig. 1) also revealed no significant difference among treat- 
ment groups. All but 10 of the 618 patients had 50% recovery 
of ST segment elevation within the 1st 24 h (of these 10 
patients, 1 received streptokinase with subcutaneous heparin, 
2 received streptokinase with intravenous heparin, 4 received 
accelerated rt-PA and 3 received combination rt-PA and 
streptokinase). Comparison of time intervals from the onset of 
pain to the initiation of thrombolytic therapy and from the 
initiation of thrombolytic therapy to the commencement of ST 
segment monitoring revealed no significant differences, al- 
though atrend toward a longer time to thrombolytic therapy in 
the combination arm was evident (Table 2). 
Time to 50% recovery of ST segment elevation from the 
onset of thrombolytic therapy as detected by each of the three 
monitoring devices also did not differ significantly among the 
four thrombolytic regimens (Fig. 2). Two-way analysis of 
variance using four thrombolytic regimens and three monitor- 
ing devices revealed no significant interaction between these 
two classes of variables (F = 0.79, p = 0.58) and no difference 
among four thrombolytic regimens (F = 0.19, p = 0.90); 
however, the difference among the monitoring devices was 
significant (F = 4.38, p = 0.013), with time to 50% resolution 
being the shortest for Holter monitoring and longest for 
continuous 12-lead ECG monitoring. 
A multiple regression model revealed that time to initiation 
Figure 1. Box plot summary statistics for time to 50% recovery of ST 
segment elevation in the four treatment groups. Median values are 
shown by lines and mean values by plus signs within the boxes; the 
length of each box is bounded by 25th and 75th percentiles. Outliers 
are shown by small squares (>1.5 to <3 interquartile ranges above the 
75th percentile) and triangles (>3 interquartile ranges above the 75th 
percentile). IV = intravenous; Sc = subcutaneous; SK = streptoki- 
nase; Time 0 = thrombolytic therapy; tPA = recombinant tissue-type 
plasminogen activator. 
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Table 2. Time to Thrombolytic Therapy, Monitoring and 50% ST Segment Recovery inthe Four Treatment Groups 
SK + SC Heparin SK + IV Heparin Accel rt-PA rt-PA + SK p 
(n = 169) (n = 144) (n = 152) (n = 153) Value 
Pain onset o therapy (min) 
Qualifying ECG to therapy (min) 
Therapy to monitor hookup (min) 
Therapy to 50% ST segment 
recovery (primary end point, min) 
156 161 160 175 0.10 
(110,232) (109,224) (120,200) (128,251) 
43 41 46 49 0.004 
(28,57) (28,63) (32,68) (36,70) 
5 6 7 11 0.9 
(-3,59) (-6,21) (-7,22) (-5,22) 
45 45 42 47 0.7 
(22,73) (24,76) (20,72) (24,66) 
Times (min) shown are median values, with 25th and 75th percentiles in parentheses. ECG = electrocardiogram; other abbreviations a in Table 1. 
of ST segment monitoring (F = 54.87, p = 0.0001) and type of 
monitoring device used (F = 9.88, p --- 0.0001) were the best 
predictors of time to 50% recovery of ST segment elevation, 
whereas time to initiation of thrombolytic therapy (F = 3.35, 
p = 0.07) and thrombolytic regimen (F = 0.63, p = 0.59) did 
not significantly predict ime to 50% of ST segment recovery. 
Stability of reperfusion. Comparison of recurrent ST seg- 
ment elevation (and indicator of reocclusion) revealed no 
difference between patients treated with streptokinase- 
containing regimens (streptokinase with intravenous or subcu- 
taneous heparin and combination group) and those who 
received accelerated rt-PA (median 0 [25th and 75th percen- 
tiles 0,1] episodes vs. 0 [0,1] episodes, p = 0.6). Recurrent ST 
segment elevation was equally frequent (p = 0.9) in patients 
treated with streptokinase with either subcutaneous (36%) or 
intravenous (36%) heparin and similar to that in patients 
receiving accelerated rt-PA (37%) or the combination treat- 
ment (34%). No difference in the frequency of recurrent ST 
elevation i  the four treatment groups was evident with the use 
of any one of the three monitoring devices. Nevertheless, the 
frequency of recurrent ST elevation detected by Holter mon- 
itoring (55%) was greater (p = 0.0001) than that seen with 
either continuous vectorcardiography (28%) or electrocardiog- 
raphy (33%). 
Recurrent ST segment elevation showed a weak trend in a 
relation with patency of infarct-related vessel (r = -0.10, p = 
0.033) and ejection fraction (r = -0.16, p = 0.001). 
Discuss ion  
The principal findings of this study are a similarity in time 
to 50% recovery of ST segment elevation and similarity in the 
frequency of recurrent ST segment elevation among the four 
thrombolytic regimens used in the GUSTO trial. 
Comparison of the patients enrolled in the main GUSTO 
trial and those participating in the ST segment monitoring 
substudy revealed no difference in baseline clinical character- 
istics and outcome. The difference in mortality in the ST 
monitoring substudy between patients treated with accelerated 
rt-PA (4.0%) and those receiving streptokinase (5.4%), al- 
though not statistically significant, was directionally similar to 
findings in the main trial (8). This observation i dicates that 
Figure 2. Box plot summary statistics for time to 50% 
recovery of ST segment elevation i  the four treat- 
ment groups as assessed by the three monitoring 
devices. Format and abbreviations as in Figure 1. 
450 
A 
350 
>,, 
> 250 
O 
O 
n,. 150 
o 100 I,O 
o 
• 50 
E ,m 
~- 0 
-50 
I11---- 
+ 
36 
A 
n 
z, n 
z, 
z, 
;tt 
v 
u)  
+ 
r/J 
Holter 
25 31  37 
n 
g, > " e, ~ "~ " + ~ ~ 0, - , .  ,o 
~¢ ~ ~ + + ~ ~ a e 
Vectorcardiographic Electrocardiographic 
77 63  69 58 55 54 48  55 
JACC Vol. 25, No. 7 1556 LANGER ET AL. 
ST SEGMENT MONITORING OF REPERFUSION June 1995:1552-7 
the sample of patients participating in the substudy was a 
representative subset of GUSTO patients. The inability to 
demonstrate a difference in time to 50% recovery, apresumed 
noninvasive surrogate measure of infarct-related artery pa- 
tency, is somewhat surprising considering that the main 
GUSTO trial (8) and the angiographic substudy (9) revealed 
greater patency at 90 rain and better outcomes in patients 
treated with accelerated rt-PA than in those treated with 
streptokinase. 
Several possible explanations for the observed results de- 
serve consideration. First, there may be no differences in time 
to reperfusion among the treatment regimens. Second, our 
ability to demonstrate a difference in time to 50% recovery of 
ST elevation may have been hampered by uncontrolled and 
variable time to initiation of ST segment monitoring or by 
differences among the devices, such as the algorithms used to 
detect and evaluate ST segment shift (10). These concerns are 
supported by the regression model that revealed that time to 
initiation of ST segment monitoring was the most significant 
factor associated with time to 50% recovery, followed closely 
by the type of ST segment monitoring device used. The 
inability to meet technical requirements in >40% of patients 
reduced the power to detect differences, although we found no 
evidence of bias introduced by technical failure. Finally, the 
choice of the end point was based on the presumption that 
time to 50% recovery would represent he most sensitive 
measure of the effect of the thrombolytic agent in achieving 
reperfusion. This end point has not been validated as the best 
measure related to patient outcome or to coronary anglo- 
graphic outcome, and subsequent analyses (11) have suggested 
that other end points representing the time to stable evidence 
of ST segment recovery may be better. These factors notwith- 
standing, the current study represents a large prospective 
assessment in the rapidly evolving field of the study of the 
speed and stability of methods of achieving coronary reperfu- 
sion. 
Recurrent ischemia as measured by episodes of recurrent 
ST segment elevation occurred in approximately one third of 
the patients and was similar in the four treatment groups; 
however, significant differences existed among monitoring 
devices. It remains unclear whether differences in ST segment 
monitoring algorithms (10), patient selection, intervention 
rates or continuity of monitoring may explain the more fre- 
quent detection of ST elevation with Holter monitoring. 
Recurrent ST segment elevation was more frequent han 
the observed rates (8,9) of reocclusion (4.9% to 6.4%), rein- 
farction (3.4% to 4.0%) or even clinically determined recur- 
rent ischemia (18.8% to 19.9%). Our findings of a similar 
frequency of recurrent ST elevation across four treatment 
groups supports the previous findings (8,9) of similar rates of 
reocclusion and reinfarction. The greater frequency of ST 
elevation than of angiographic reocclusion may be partly 
related to differences in the assessment of myocardial perfu- 
sion and recurrent ischemia as detected by continuous ST 
segment monitoring versus a single determination of patency 
with coronary angiography. Our findings of a weak relation 
between recurrent ST segment elevation and patency of the 
infarct-related vessel and ejection fraction extend our previous 
observations of the prognostic significance of ST segment 
depression on Holter monitoring after acute myocardial infarc- 
tion in relation to severity of stenosis of the culprit lesion and 
lack of improvement in left ventricular function (12). 
Conclusions. ST segment monitoring for detection of myo- 
cardial reperfusion and recurrent ischemia fter thrombolytic 
therapy as defined in this GUSTO substudy did not demon- 
strate a difference among patients treated with accelerated 
rt-PA, streptokinase with intravenous or subcutaneous hepa- 
rin, or combination rt-PA and streptokinase. The technical and 
study design limitations resulted in diminished sensitivity to 
detect differences in time to 50% recovery of ST segment 
elevation among the four treatment groups. Although assess- 
ment of the frequency of recurrent ischemia was related to the 
type of monitoring device, the lack of difference in this primary 
end point among treatments upports the observations of 
similar reocclusion and reinfarction rates in the main GUSTO 
trial and angiographic substudy. Further insight regarding the 
pathophysiology of myocardial perfusion early after thrombol- 
ysis based on ST segment monitoring may come from addi- 
tional post hoc analyses of these data. Nevertheless, ST 
segment monitoring may be used to compare different reper- 
fusion strategies in the future, provided that the methodology 
of monitoring is improved. 
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